Overview ROMEO (Rosuvastatin in Metabolic syndrOme) Status: Completed Trial end date: 2008-06-01 Target enrollment: Participant gender: Summary The primary objective of this study is to compare the effect of rosuvastatin 10mg with atorvastatin 10mg after 6 weeks of treatment in the ratio of ApoB/ApoA1 in subjects with metabolic syndrome. Phase: Phase 4 Details Lead Sponsor: AstraZenecaTreatments: AtorvastatinAtorvastatin CalciumRosuvastatin Calcium